162 related articles for article (PubMed ID: 38092740)
1. Transcriptome reprogramming through alternative splicing triggered by apigenin drives cell death in triple-negative breast cancer.
Sudhakaran M; Navarrete TG; Mejía-Guerra K; Mukundi E; Eubank TD; Grotewold E; Arango D; Doseff AI
Cell Death Dis; 2023 Dec; 14(12):824. PubMed ID: 38092740
[TBL] [Abstract][Full Text] [Related]
2. Apigenin by targeting hnRNPA2 sensitizes triple-negative breast cancer spheroids to doxorubicin-induced apoptosis and regulates expression of ABCC4 and ABCG2 drug efflux transporters.
Sudhakaran M; Parra MR; Stoub H; Gallo KA; Doseff AI
Biochem Pharmacol; 2020 Dec; 182():114259. PubMed ID: 33011162
[TBL] [Abstract][Full Text] [Related]
3. Apigenin and its combination with Vorinostat induces apoptotic-mediated cell death in TNBC by modulating the epigenetic and apoptotic regulators and related miRNAs.
Nimal S; Kumbhar N; Saruchi ; Rathore S; Naik N; Paymal S; Gacche RN
Sci Rep; 2024 Apr; 14(1):9540. PubMed ID: 38664447
[TBL] [Abstract][Full Text] [Related]
4. Cancer-Associated MORC2-Mutant M276I Regulates an hnRNPM-Mediated CD44 Splicing Switch to Promote Invasion and Metastasis in Triple-Negative Breast Cancer.
Zhang FL; Cao JL; Xie HY; Sun R; Yang LF; Shao ZM; Li DQ
Cancer Res; 2018 Oct; 78(20):5780-5792. PubMed ID: 30093560
[TBL] [Abstract][Full Text] [Related]
5. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer.
Yu S; Hu C; Liu L; Cai L; Du X; Yu Q; Lin F; Zhao J; Zhao Y; Zhang C; Liu X; Li W
J Transl Med; 2020 Jul; 18(1):286. PubMed ID: 32723333
[TBL] [Abstract][Full Text] [Related]
7. The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.
Naro C; De Musso M; Delle Monache F; Panzeri V; de la Grange P; Sette C
J Exp Clin Cancer Res; 2021 Dec; 40(1):397. PubMed ID: 34930366
[TBL] [Abstract][Full Text] [Related]
8. Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer.
Zhen Y; Zhao R; Wang M; Jiang X; Gao F; Fu L; Zhang L; Zhou XL
Theranostics; 2020; 10(18):8080-8097. PubMed ID: 32724459
[No Abstract] [Full Text] [Related]
9. TRA2A Promoted Paclitaxel Resistance and Tumor Progression in Triple-Negative Breast Cancers via Regulating Alternative Splicing.
Liu T; Sun H; Zhu D; Dong X; Liu F; Liang X; Chen C; Shao B; Wang M; Wang Y; Sun B
Mol Cancer Ther; 2017 Jul; 16(7):1377-1388. PubMed ID: 28416606
[TBL] [Abstract][Full Text] [Related]
10. SF3A2 promotes progression and cisplatin resistance in triple-negative breast cancer via alternative splicing of MKRN1.
Deng L; Liao L; Zhang YL; Yang SY; Hu SY; Andriani L; Ling YX; Ma XY; Zhang FL; Shao ZM; Li DQ
Sci Adv; 2024 Apr; 10(14):eadj4009. PubMed ID: 38569025
[TBL] [Abstract][Full Text] [Related]
11. Obesity-induced MBD2_v2 expression promotes tumor-initiating triple-negative breast cancer stem cells.
Teslow EA; Mitrea C; Bao B; Mohammad RM; Polin LA; Dyson G; Purrington KS; Bollig-Fischer A
Mol Oncol; 2019 Apr; 13(4):894-908. PubMed ID: 30636104
[TBL] [Abstract][Full Text] [Related]
12. The Alternative Splicing of Cytoplasmic Polyadenylation Element Binding Protein 2 Drives Anoikis Resistance and the Metastasis of Triple Negative Breast Cancer.
Johnson RM; Vu NT; Griffin BP; Gentry AE; Archer KJ; Chalfant CE; Park MA
J Biol Chem; 2015 Oct; 290(42):25717-27. PubMed ID: 26304115
[TBL] [Abstract][Full Text] [Related]
13. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
[TBL] [Abstract][Full Text] [Related]
14. Molecular basis for the action of a dietary flavonoid revealed by the comprehensive identification of apigenin human targets.
Arango D; Morohashi K; Yilmaz A; Kuramochi K; Parihar A; Brahimaj B; Grotewold E; Doseff AI
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):E2153-62. PubMed ID: 23697369
[TBL] [Abstract][Full Text] [Related]
15. MCPIP1-mediated NFIC alternative splicing inhibits proliferation of triple-negative breast cancer via cyclin D1-Rb-E2F1 axis.
Chen F; Wang Q; Yu X; Yang N; Wang Y; Zeng Y; Zheng Z; Zhou F; Zhou Y
Cell Death Dis; 2021 Apr; 12(4):370. PubMed ID: 33824311
[TBL] [Abstract][Full Text] [Related]
16. PCMT1 knockdown attenuates malignant properties by globally regulating transcriptome profiles in triple-negative breast cancer cells.
Saiding A; Maimaitiyiming D; Chen M; Yan F; Chen D; Hu X; Shi P
PeerJ; 2023; 11():e16006. PubMed ID: 37953789
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
18. Transcriptomic profiles-based approach to decode the role of miR-122 in triple negative breast cancer.
Flores Fortis M; Perez Añorve IX; Del Moral Hernandez O; Villegas N; Arechaga Ocampo E
Genes Chromosomes Cancer; 2023 Jul; 62(7):392-404. PubMed ID: 36695641
[TBL] [Abstract][Full Text] [Related]
19. Protein arginine methyltransferase 5: A novel therapeutic target for triple-negative breast cancers.
Vinet M; Suresh S; Maire V; Monchecourt C; Némati F; Lesage L; Pierre F; Ye M; Lescure A; Brisson A; Meseure D; Nicolas A; Rigaill G; Marangoni E; Del Nery E; Roman-Roman S; Dubois T
Cancer Med; 2019 May; 8(5):2414-2428. PubMed ID: 30957988
[TBL] [Abstract][Full Text] [Related]
20. NFIB promotes cell survival by directly suppressing p21 transcription in TP53-mutated triple-negative breast cancer.
Liu RZ; Vo TM; Jain S; Choi WS; Garcia E; Monckton EA; Mackey JR; Godbout R
J Pathol; 2019 Feb; 247(2):186-198. PubMed ID: 30350349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
